Fundraising Fox

🦊/Companies

Inanovate

Sioux Falls, US · Delaware corporation

Find your way into Inanovate

407 people in our graph share verified history with the Inanovate team — schools, employers, funds. One of them is your warm intro.

Eghosa Omoiguiunlockedknows David Ure · together at Babson College (overlapped)

×3knows the team · via Babson College

×7knows the team · via Babson F.W. Olin Graduate School of Business

knows the team · via University of Birmingham

Inanovate is a diagnostics company that developed Lyme-ID, an FDA 510(k)-cleared blood test for Lyme disease based on its proprietary Bio-ID technology. The test uses an at-home blood collection kit that is mailed to a CLIA-certified laboratory, with results delivered through an online portal in as little as 24 hours.

Founders & leadership

DU

David Ure inChairman & FounderDavid Ure founded Inanovate after building and selling two previous business ventures and spending over a decade consulting on startup and growth strategy; he holds an M.S. in Nuclear Physics from the University of Birmingham and an MBA from Babson College.

JE

James E OuryExecutive

Board

BC

Blaine CrissmanBoard director

KP

Katie PohlsonBoard director

PD

Peter D. LosBoard director

DA

David ArslanianBoard director

GH

George HolmesBoard director

MH

Michael H. GoldsteinBoard Member

RM

Randall MarfinBoard Member

Reported raises · per SEC filings

Form D private placements

$13M disclosed across 10 rounds · 2015–2025

▶$808KraisedJul 2025 · 2 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

David UreExecutive Officer, Director
Peter D LosDirector
George HolmesDirector
Blaine CrissmanDirector
David ArslanianDirector
James E OuryExecutive Officer
Katie PohlsonDirector

Offering amount: $808K
Amount sold: $808K
Minimum investment: $10K
Proceeds to insiders: $50K
First sale: Mar 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$900KraisedNov 2024 · 6 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Blaine CrissmanDirector
Katie PohlsonDirector
David UreExecutive Officer, Director
Peter D LosDirector
James E OuryExecutive Officer
David ArslanianDirector
George HolmesDirector

Offering amount: $900K
Amount sold: $900K
Minimum investment: $10K
Proceeds to insiders: $100K
First sale: Nov 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$1.1MraisedJun 2024 · 4 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Katie PohlsonDirector
James E OuryExecutive Officer
Blaine CrissmanDirector
David ArslanianDirector
David UreExecutive Officer, Director
George HolmesDirector
Peter D LosDirector

Offering amount: $2.5M
Amount sold: $1.1M
Minimum investment: $25K
Proceeds to insiders: $300K
First sale: May 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$1.5MraisedDec 2023 · 3 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

David ArslanianDirector
Blaine CrissmanDirector
Katie PohlsonDirector
George HolmesDirector
Peter D LosDirector
James E OuryExecutive Officer
David UreExecutive Officer, Director

Offering amount: $3M
Amount sold: $1.5M
Minimum investment: $10K
Proceeds to insiders: $300K
First sale: Dec 2023
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$2.4MraisedOct 2022 · 7 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Kent LehrDirector
David UreExecutive Officer
James E OuryExecutive Officer
Kamran TahamtanzadeDirector
George HolmesDirector
David ArslanianDirector
Peter D LosDirector
Blaine CrissmanDirector

Offering amount: $3M
Amount sold: $2.4M
Minimum investment: $10K
Proceeds to insiders: $300K
First sale: Oct 2022
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$1.8MraisedFeb 2022 · 11 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Peter D LosDirector
George HolmesDirector
Michael GoldsteinDirector
Blaine CrissmanDirector
David UreExecutive Officer
David ArslanianDirector
James E OuryDirector

Offering amount: $1.8M
Amount sold: $1.8M
Minimum investment: $10K
Proceeds to insiders: $300K
First sale: Feb 2022
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$455.3KraisedJul 2020 · 6 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

David UreExecutive Officer
Michael GoldsteinDirector
Peter D LosDirector
Blaine CrissmanDirector
George HolmesDirector
David ArslanianDirector
James E OuryDirector

Offering amount: $455.3K
Amount sold: $455.3K
Minimum investment: $10K
Proceeds to insiders: $25K
First sale: Jul 2020
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$439.2KraisedNov 2019 · 3 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

David UreExecutive Officer
James E OuryDirector
Peter D LosDirector
George HolmesDirector
Michael GoldsteinDirector
David ArslanianDirector
Blaine CrissmanDirector

Offering amount: $439.2K
Amount sold: $439.2K
Minimum investment: $10K
Proceeds to insiders: $25K
First sale: Nov 2019
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

In8Bio3 shared keywordsIN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for solid and hematological tumors using its DeltEx platform (allogeneic, autologous, iPSC, and genetically modified approaches). Its lead candidates include INB-400 and INB-200 for glioblastoma and INB-100 for leukemia patients undergoing bone marrow transplantation.

Companies competing with Inanovate for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 5 SBIR/STTR awards

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Science Foundation	Phase I	2021	$255.9K
National Institutes of Health (NIH)National Institutes of Health	Phase II	2018	$2M
National Institutes of Health (NIH)National Institutes of Health	Phase I	2017	$300K
National Institutes of Health (NIH)National Institutes of Health	Phase II	2011	$1.5M
National Institutes of Health (NIH)National Institutes of Health	Phase I	2009	$199.2K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Inanovate do?: Inanovate is a diagnostics company that developed Lyme-ID, an FDA 510(k)-cleared blood test for Lyme disease based on its proprietary Bio-ID technology. The test uses an at-home blood collection kit that is mailed to a CLIA-certified laboratory, with results delivered through an online portal in as little as 24 hours.
How much funding has Inanovate raised?: Inanovate has disclosed $13M raised across 10 rounds.
Where is Inanovate headquartered?: Inanovate is headquartered in Sioux Falls, US.